At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Panobinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Panobinostat and Bicalutamide for Prostate Cancer and Prostatic Neoplasms. Completed, enrolled 52 participants across 4 sites.
Detailed Summary
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer. This trial is at its Phase II stage. As of July 23, 2013 Arm B was closed to accrual, all the remaining slots in accrual will be allocated to Arm A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostatic Neoplasms
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartJun 2009
Primary CompletionMar 2015
Study CompletionJul 2015
TodayJul 2026
First PostedApr 9, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 17.2 years ago
Interventions
Panobinostatdrug
Bicalutamidedrug